CompanyABSINasdaqVancouver, WA

Absci Corp

Absci develops biologics using generative AI and synthetic biology.

SEC EDGAR ClinicalTrials.gov investors.absci.com

10-QAug 11Latest SEC filing, period to Jun 30

Aug 11Latest story

August 2026

Absci reports Q2 2026 results, positive ABS-201 Phase 1 data, $100M raise with Lilly

Aug 11Quarterly updateAbsci Corp Eli Lilly